Cargando…

Treatment Options Available for COVID-19 and an Analysis on Possible Role of Combination of rhACE2, Angiotensin (1-7) and Angiotensin (1-9) as Effective Therapeutic Measure

Corona virus disease (COVID-19), caused by SARS-CoV-2, is rapidly spreading all around the world and is posing a threat to mankind. Since SARS-CoV-2 is a novel virus, little is known about it and no effective drug is available for its treatment. While many drugs are being evaluated, an effective the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muslim, Shahnawaz, Nasrin, Nasrin, Alotaibi, Faisal Obaid, Prasad, Geeta, Singh, Shambhu Kumar, Alam, Izhar, Mustafa, Gulam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Covid-19
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442548/ https://www.ncbi.nlm.nih.gov/pubmed/32864572 http://dx.doi.org/10.1007/s42399-020-00407-9

Ejemplares similares

Angiotensin‐converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin‐converting enzyme 2 in patients with cardiovascular disease
por: Lebek, Simon, et al.
Publicado: (2020)

Response to the Comment ‘Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019
por: Komiyama, Maki, et al.
Publicado: (2020)

The Renin–Angiotensin–Aldosterone System and Coronavirus Disease 2019
por: Coto, Eliecer, et al.
Publicado: (2021)

RhACE2 – playing an important role in inhibiting apoptosis induced by Ang II in HUVECs
por: Zhang, Hongli, et al.
Publicado: (2019)

Angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID‐19 infection in a multi‐site UK acute hospital trust
por: Bean, Daniel M., et al.
Publicado: (2020)

Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study
por: Kim, Ju Hwan, et al.
Publicado: (2020)

An analysis of fatal adverse conditions in temporal association of COVID-19 vaccination to boost the safety of vaccination for COVID-19
por: Muslim, Shahnawaz, et al.
Publicado: (2023)

rhACE2 Therapy Modifies Bleomycin-Induced Pulmonary Hypertension via Rescue of Vascular Remodeling
por: Rathinasabapathy, Anandharajan, et al.
Publicado: (2018)

Myocardial fibrosis reversion via rhACE2-electrospun fibrous patch for ventricular remodeling prevention
por: Qiu, Zeping, et al.
Publicado: (2021)

COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients
por: Genet, Bastien, et al.
Publicado: (2020)

The effect of angiotensin-converting enzyme levels on COVID-19 susceptibility and severity: a Mendelian randomization study
por: Butler-Laporte, Guillaume, et al.
Publicado: (2020)

Angiotensin II induces reactive oxygen species, DNA damage, and T-cell apoptosis in severe COVID-19
por: Kundura, Lucy, et al.
Publicado: (2022)

Association between renin–angiotensin–aldosterone system inhibitor use and COVID‐19 hospitalization and death: a 1.4 million patient nationwide registry analysis
por: Savarese, Gianluigi, et al.
Publicado: (2020)

COVID‐19, hypertension, and renin‐angiotensin‐aldosterone system inhibitors: Much ado about nothing or real problem to be solved?
por: Tadic, Marijana, et al.
Publicado: (2020)

Influence of blood pressure control and application of renin‐angiotensin‐aldosterone system inhibitors on the outcomes in COVID‐19 patients with hypertension
por: Chen, Renzheng, et al.
Publicado: (2020)

Angiotensin converting enzyme and sodium glucose cotransporter inhibitors alleviate inflammatory effects of SARS-CoV-2 in cardiomyocytes
por: Wong, Chun-Ka, et al.
Publicado: (2022)

Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection
por: Vitiello, Antonio, et al.
Publicado: (2021)

WCN23-0291 USE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACEIs) AND ANGIOTENSIN-RECEPTOR BLOCKERS (ARBs) AND INCIDENCE OF PNEUMONIA OR INFLUENZA OR COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Qin, X., et al.
Publicado: (2023)

The Renin-Angiotensin system and SARS-CoV-2 infection: A role for the ACE2 receptor?
por: Sever, Peter, et al.
Publicado: (2020)

Combination of C21 and ARBs with rhACE2 as a therapeutic protocol: A new promising approach for treating ARDS in patients with coronavirus infection
por: Soheili, Marzieh, et al.
Publicado: (2020)

COVID-19 Outbreak: an Update on Therapeutic Options
por: Panati, Kalpana, et al.
Publicado: (2020)

Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells
por: Kimura, Hiroki, et al.
Publicado: (2020)

The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients
por: Harky, Amer, et al.
Publicado: (2021)

Angiotensin-converting enzyme 2, the SARS-CoV-2 cellular receptor, is widely expressed in human myometrium and uterine leiomyoma
por: Racilan, Alexon M, et al.
Publicado: (2021)

Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients
por: Osman, Ikram Omar, et al.
Publicado: (2021)

Involvement of Spike Protein, Furin, and ACE2 in SARS-CoV-2-Related Cardiovascular Complications
por: Ming, Yi, et al.
Publicado: (2020)

Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT(1) receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axis
por: Iwai, Masaru, et al.
Publicado: (2009)

Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon
por: Finney, Lydia J., et al.
Publicado: (2021)

The role of renin-angiotensin system activated phagocytes in the SARS-CoV-2 coronavirus infection
por: Göbölös, Laszlo, et al.
Publicado: (2021)

ACE2: Angiotensin II/Angiotensin-(1–7) Balance in Cardiac and Renal Injury
por: Varagic, Jasmina, et al.
Publicado: (2014)

Long-term strategies to control COVID-19 in low and middle-income countries: an options overview of community-based, non-pharmacological interventions
por: Chowdhury, Rajiv, et al.
Publicado: (2020)

Renin-Angiotensin System and Sex Differences in COVID-19: A Critical Assessment
por: Chappell, Mark C.
Publicado: (2023)

Structural determinants for binding to angiotensin converting enzyme 2 (ACE2) and angiotensin receptors 1 and 2
por: Clayton, Daniel, et al.
Publicado: (2015)

Angiotensin II, III, and IV may be important in the progression of COVID-19
por: Cure, Erkan, et al.
Publicado: (2020)

Availability of Internationally Controlled Essential Medicines in the COVID-19 Pandemic
por: Pettus, Katherine, et al.
Publicado: (2020)

Increased ACE2 Expression in Bronchial Epithelium of COPD Patients who are Overweight
por: Higham, Andrew, et al.
Publicado: (2020)

ACE2 and Angiotensin-(1-7) in Hypertensive Renal Disease
por: Moon, Ju-Young
Publicado: (2011)

Lung ACE2 and ADAM17 in pulmonary arterial hypertension: Implications for COVID-19?
por: Pérez-Vizcaíno, Francisco
Publicado: (2020)

Assessing the availability and quality of COVID-19 mortality data in Europe: a comparative analysis
por: Marinković, Ivan, et al.
Publicado: (2023)

Angiotensin(1-7) and ACE2, “The Hot Spots” of Renin-Angiotensin System, Detected in the Human Aqueous Humor
por: Holappa, Mervi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2inmar0t5im7o2li089v575vb4